Literature DB >> 23497767

Sitagliptin--another option for managing type 2 diabetes in dialysis patients?

Wendy L St Peter, Eric D Weinhandl, Michael F Flessner.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23497767     DOI： 10.1053/j.ajkd.2013.01.004

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN： 0272-6386            Impact factor:   8.860


× No keyword cloud information.
  4 in total

Review 1.  Pharmacokinetics and clinical use of incretin-based therapies in patients with chronic kidney disease and type 2 diabetes.

Authors:  André J Scheen
Journal:  Clin Pharmacokinet       Date:  2015-01       Impact factor: 6.447

Review 2.  New models of chronic kidney disease care including pharmacists: improving medication reconciliation and medication management.

Authors:  Wendy L St Peter; Lori D Wazny; Uptal D Patel
Journal:  Curr Opin Nephrol Hypertens       Date:  2013-11       Impact factor: 2.894

Review 3.  Defining, Treating, and Understanding Chronic Kidney Disease--A Complex Disorder.

Authors:  Dean Campbell; Matthew R Weir
Journal:  J Clin Hypertens (Greenwich)       Date:  2015-04-27       Impact factor: 3.738

4.  Sitagliptin and risk of heart failure hospitalization in patients with type 2 diabetes on dialysis: A population-based cohort study.

Authors:  Yi-Chih Hung; Che-Chen Lin; Wei-Lun Huang; Man-Ping Chang; Ching-Chu Chen
Journal:  Sci Rep       Date:  2016-07-27       Impact factor: 4.379
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.